Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Late-Cycle Approval Predictions Not A Good Idea, FDA Says

Executive Summary

OND Director John Jenkins says the late-cycle meeting in the new PDUFA review model will offer a lot of information to sponsors, but likely will not be predictive of application approvability.


Related Content

PDUFA V ‘Program’ Gets Positive Evaluation – Except For Inspections
ANDA Sponsors May Receive Early Notification Of Upcoming Actions, Woodcock Says
First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?
PDUFA Communications Hurt By Sequestration As Late-Stage Meetings Begin
PDUFA V and Investor Communications
PDUFA V and Investor Communications
CDER Is Stressing Consistency As It Rolls Out FDASIA Programs
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
“Emerging Sponsors” Pose Regulatory, Public Relations Challenges For Drug Review Process, FDA’s Jenkins Says
Pre-NDA Work Takes Added Importance As PDUFA V Stretches Review Cycle





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts